While studying and communicating with colleagues on the “ClinCaseQuest” simulation training platform, you can set up the automatic notifications you wish to receive by E-mail.

Automatic Platform notifications will always appear in the top horizontal menu in the “Bell” tab, or in the drop-down vertical menu in the “Notifications” section – unread and read.

If you would like to receive notifications by E-mail, in the top drop-down menu, click the “Edit Account” tab. On the account settings page in the sidebar, select the “E-mail notification settings” tab. The “E-mail notification settings” page will open.

You can set parameters or receive the following E-mail notifications:

• those related to communication in your activity feed (your personal user feed) – if a member referred to you in the post or one of the members responded to your post or comment (select “Yes” or “No”);
• when receiving private messages in the Platform messenger – “The user has sent you a new message” (select “Yes” or “No”);
• regarding activity in social groups (medical communities of the Platform), if:
  • the user invited you to join the group;
  • group information has been updated;
  • you have been promoted to group organizer or moderator;
  • a member is requesting permission to join a private group you lead;
  • your request to join the group has been approved or denied;
• regarding forum activity (discussions, discussions) if:
  • a member responded to a discussion you signed up for;
  • a member created a discussion in the forum you signed up for;
• related to peer connections if:
  • a member invites you to connect;
  • a member accepts your connection request.

Once you have selected the E-mail notification settings that are convenient for you, click “Save Changes”. You will now receive the notifications you have chosen to receive in your E-mail.

Register on our website right now to have access to more learning materials!

Register

Charlson Comorbidity Index (CCI) Online Calculator

May 10, 2023

Charlson Comorbidity Index predicts 10-year survival in patients with multiple comorbidities.

Loading...

Email (indicate if you want the results to be sent to your email)

Date of assessment

---

Age *

<50 years

50–59 years

60–69 years

70–79 years

≥80 years

Myocardial infarction *

History of definite or probable MI (EKG changes and/or enzyme changes)

No

Yes

Congestive heart failure *

Exertional or paroxysmal nocturnal dyspnea and has responded to digitalis, diuretics, or afterload reducing agents

No

Yes

Peripheral vascular disease *

Intermittent claudication or past bypass for chronic arterial insufficiency, history of gangrene or acute arterial insufficiency, or untreated thoracic or abdominal aneurysm (≥6 cm)

No

Yes

Cerebrovascular accident or Transient ischemic attack *

History of a cerebrovascular accident with minor or no residua and transient ischemic attacks

No

Yes

Dementia *

Chronic cognitive deficit

No

Yes

Chronic obstructive pulmonary disease *

No

Yes

Connective tissue disease *

No

Yes

Peptic ulcer disease *

Any history of treatment for ulcer disease or history of ulcer bleeding

No

Yes

Liver disease *

Severe = cirrhosis and portal hypertension with variceal bleeding history, moderate = cirrhosis and portal hypertension but no variceal bleeding history, mild = chronic hepatitis (or cirrhosis without portal hypertension)

None

Mild

Moderate to severe

Diabetes mellitus *

None or diet-controlled

Uncomplicated

End-organ damage

Hemiplegia *

No

Yes

Moderate to severe chronic kidney disease *

Severe = on dialysis, status post kidney transplant, uremia, moderate = creatinine >3 mg/dL (0.27 mmol/L)

No

Yes

Solid tumor *

None

Localized

Metastatic

Leukemia *

No

Yes

Lymphoma *

No

Yes

AIDS *

No

Yes

---

Charlson Comorbidity Index

10-year survival

Details:

Reset

* Required

VariablePointsAge <50…

Read More

Multiple Myeloma Diagnostic Criteria – Online Calculator

February 5, 2023

Loading...

Email (indicate if you want the results to be sent to your email)

Date of assessment

---

≥1 of the following (A or B)

*

A. Clonal bone marrow plasma cells ≥10%

B. Biopsy-proven bony or extramedullary plasmacytoma

≥1 myeloma defining event (C1 or C2)

• C1. End organ damage attributable to underlying plasma cell disorder (≥1 of the following): *

o Hypercalcemia (Serum calcium >1 mg/dL (>0.25 mmol/L) higher than upper limit of normal or >11 mg/dL (>2.75 mmol/L))

o Renal insufficiency (Creatinine clearance<40 mL per min or serum creatinine >2 mg/dL (177 μmol/L))

o Anemia (Hemoglobin >2 g/dL (20 g/L) below lower limit of normal

o Bone lesions (≥1 osteolytic lesion on skeletal x-ray

• C2. ≥1 of the following biomarkers of malignancy: *

o Clonal bone marrow plasma cells ≥60%

o Involved:uninvolved sFLC ratio ≥100

o >1 focal lesion on MRI

---

Result

Diagnostic result Negative. Not positive for multiple myeloma by IMWG criteria

Diagnostic result Positive for multiple myeloma by IMWG criteria

Details:

Reset

* Required

For Multiple Myeloma Diagnostic Criteria assessment necessary to provide selection of the…

Read More

Revised Multiple Myeloma International Staging System (R-ISS) Online Calculator

January 17, 2023

Revised Multiple Myeloma International Staging System (R-ISS) – prognostication tool for myeloma patients based on…

Read More

Multiple Myeloma International Staging System (ISS) Online Calculator

January 16, 2023

Multiple Myeloma International Staging System (ISS) prognosticates the severity of multiple myeloma based on routinely…

Read More

SAVED VTE Score

January 11, 2023

SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulators. [ezfc…

Read More

IMPEDE VTE Score

January 11, 2023

IMPEDE score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulators. [ezfc…

Read More